Last reviewed · How we verify
Low-dose intravenous tenecteplase
Tenecteplase is a fibrinolytic agent that converts plasminogen to plasmin, breaking down fibrin clots to restore blood flow.
Tenecteplase is a fibrinolytic agent that converts plasminogen to plasmin, breaking down fibrin clots to restore blood flow. Used for Acute ischemic stroke (phase 3 investigation), Acute myocardial infarction (potential indication).
At a glance
| Generic name | Low-dose intravenous tenecteplase |
|---|---|
| Sponsor | The George Institute |
| Drug class | Fibrinolytic agent / Tissue plasminogen activator (tPA) |
| Target | Plasminogen / Fibrin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Tenecteplase is a tissue plasminogen activator (tPA) variant engineered for improved fibrin specificity and longer half-life compared to alteplase. At low intravenous doses, it selectively activates fibrin-bound plasminogen, promoting thrombolysis while minimizing systemic fibrinogenolysis. This mechanism aims to restore perfusion in acute thrombotic conditions with potentially reduced bleeding risk compared to standard-dose thrombolytics.
Approved indications
- Acute ischemic stroke (phase 3 investigation)
- Acute myocardial infarction (potential indication)
Common side effects
- Intracranial hemorrhage
- Systemic bleeding
- Reperfusion arrhythmias
- Hypotension
Key clinical trials
- Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients (PHASE4)
- ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 (PHASE3)
- Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits (PHASE4)
- A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion (PHASE3)
- ACT-GLOBAL Adaptive Platform Trial for Stroke (PHASE3)
- CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase (PHASE2)
- Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low-dose intravenous tenecteplase CI brief — competitive landscape report
- Low-dose intravenous tenecteplase updates RSS · CI watch RSS
- The George Institute portfolio CI